NanoLogix BioTechnology announces:
1) The completion of N-Assay primary research by researchers in Houston, Texas. The research paper is being finalized for submission to a noted peer-reviewed journal. The research was on three bacteria --- Neisseria Gonorrhea, Group B Streptococcus, and Enterococcus and was focused upon their rapid detection, identification, and the determination of their antibiotic resistance and sensitivity to multiple antibiotics. The results, in a few words, are: very positive, huge, phenomenal, great, unprecedented , to say the least.
The N-Assay appears to work rapidly to identify any bacteria for which there exists an antibody.
2) With the delivery today of 100,000+ petri plates, NanoLogix Biotechnology has moved exclusively to using petri plates from Gosselin (A Corning company). The Gosselin products, previously purchased by the Company in 50,000+ plate lots, have enabled the company to increase economy of scale by 20% over other manufacturers' products
3) NanoLogix has reached an agreement with a multi-billion dollar medical technology company to customize the N-Assay diagnostic technology for their requirements. The work is being financed by the client and upon successful completion is projected to result in sales of multiple thousands of N-Assay kits.
4) The largest single-customer, single-day sale in the history of the company has just occurred , for an amount in excess of $30,000.00 The order was for agar-filled petri plates.
Note: The company and its management have received numerous communications from shareholders concerned with the perceived delay in results of the N-Assay study and how the N-Assay fits with the BNF technology. The answer to these queries is this:
Researchers were furnished batches of antibodies from the premier antibody suppliers in the United States. When those antibodies are not of the quality previously received from the suppliers, then other premier suppliers are sourced. This is not an instant process.
Under personnel and financial resource constraints previously addressed, what NanoLogix BioTechnolgy does should not be viewed as one would view what major biotech accomplish for timelines.
The N-Assay is a non-subjective, computer-readable ELISA diagnostic. The BNF is not, period. We will focus upon what is the best technology, which is the N-Assay.
All of this information, and more, will soon be released in a public press release for the use of the media.
This message was sent to geo_costo@hotmail.com from:
NanoLogix | news@nanologix.com | NanoLogix | 843 North Main Street | Hubbard, OH 44425
1) The completion of N-Assay primary research by researchers in Houston, Texas. The research paper is being finalized for submission to a noted peer-reviewed journal. The research was on three bacteria --- Neisseria Gonorrhea, Group B Streptococcus, and Enterococcus and was focused upon their rapid detection, identification, and the determination of their antibiotic resistance and sensitivity to multiple antibiotics. The results, in a few words, are: very positive, huge, phenomenal, great, unprecedented , to say the least.
The N-Assay appears to work rapidly to identify any bacteria for which there exists an antibody.
2) With the delivery today of 100,000+ petri plates, NanoLogix Biotechnology has moved exclusively to using petri plates from Gosselin (A Corning company). The Gosselin products, previously purchased by the Company in 50,000+ plate lots, have enabled the company to increase economy of scale by 20% over other manufacturers' products
3) NanoLogix has reached an agreement with a multi-billion dollar medical technology company to customize the N-Assay diagnostic technology for their requirements. The work is being financed by the client and upon successful completion is projected to result in sales of multiple thousands of N-Assay kits.
4) The largest single-customer, single-day sale in the history of the company has just occurred , for an amount in excess of $30,000.00 The order was for agar-filled petri plates.
Note: The company and its management have received numerous communications from shareholders concerned with the perceived delay in results of the N-Assay study and how the N-Assay fits with the BNF technology. The answer to these queries is this:
Researchers were furnished batches of antibodies from the premier antibody suppliers in the United States. When those antibodies are not of the quality previously received from the suppliers, then other premier suppliers are sourced. This is not an instant process.
Under personnel and financial resource constraints previously addressed, what NanoLogix BioTechnolgy does should not be viewed as one would view what major biotech accomplish for timelines.
The N-Assay is a non-subjective, computer-readable ELISA diagnostic. The BNF is not, period. We will focus upon what is the best technology, which is the N-Assay.
All of this information, and more, will soon be released in a public press release for the use of the media.
This message was sent to geo_costo@hotmail.com from:
NanoLogix | news@nanologix.com | NanoLogix | 843 North Main Street | Hubbard, OH 44425
